INTRODUCTION {#s1}
============

Cancer describes a group of diseases characterized by the uncontrolled growth and spread of abnormal cells \[[@R1]\]. It is the leading cause of death in economically developed countries and the second leading cause of death in developing countries \[[@R2]\]. According to statistics, a total of 1,658,370 new cancer cases and 589,430 cancer deaths were projected to occur in the United States in 2015 \[[@R3]\]. In general, cancer is the result of multiple environmental and genetic risk factors, as well as gene-environment interactions \[[@R4]\]. Among genetic factors, genetic and epigenetic mutations, such as aberrant DNA methylation, can lead to carcinogenesis \[[@R1]\].

Recently, the relationship between genetic polymorphisms and the risk of cancer has been widely researched. Among the polymorphic genes, excision repair cross-complementing group 2 (*ERCC2*), also called xeroderma pigmentosum group D (*XPD*), plays important roles in the nucleotide excision repair (NER) pathway \[[@R5]\]. The *ERCC2* gene is located on chromosome 19q13.3, comprises 23 exons, and spans approximately 54,000 base pairs \[[@R6]\]. It encodes an evolutionarily conserved helicase, which has ATP-dependent helicase activity within its multi subunit core transcription factor IIH (TFIIH). The helicase participates in DNA unwinding as part of the NER pathway, and plays an important role in the recognition and repair of structurally unrelated DNA lesions containing bulky adducts and thymidine dimers \[[@R7], [@R8]\]. Some studies have shown that *ERCC2* polymorphisms may be related to reduced DNA repair due to a possible reduction in its helicase activity \[[@R9], [@R10]\].

There are two important single nucleotide polymorphisms (SNPs) in the *ERCC2* gene. One is the Lys751Gln polymorphism, which has been shown to be involved in genetic susceptibility to some cancer types. Another common *ERCC2* polymorphism in the coding region is Asp312Asn (rs1799793) \[[@R11]\], which is characterized by a G to A transition at position 312 in exon 10 causing an aspartic acid (Asp) to asparagine amino acid (Asn) exchange \[[@R12]\]. This polymorphism has been widely studied for its association with susceptibility to cancer including brain \[[@R13]\], esophageal \[[@R14]--[@R16]\], head and neck \[[@R11]\], bladder \[[@R17]--[@R19]\], and breast cancers \[[@R20]--[@R22]\]. However, the results reported by these studies were inconsistent.

To provide a comprehensive assessment of and to clarify associations between the *ERCC2* Asp312Asn polymorphisms and the risk of cancer, we performed a meta-analysis of all the eligible case-control studies.

RESULTS {#s2}
=======

Eligible studies {#s2_1}
----------------

A total of 449 articles were reviewed, and eventually 86 articles with 38,848 cases and 48,928 controls met the inclusion criteria. Among these publications, there was 1 osteosarcoma \[[@R23]\], 1 hepatocellular cancer (HCC) \[[@R24]\], 3 oral cancer \[[@R25]--[@R27]\], 5 skin cancer \[[@R28]--[@R32]\], 5 colorectal cancer \[[@R23], [@R33]--[@R36]\], 6 head and neck cancer \[[@R37]--[@R42]\], 6 esophageal cancer \[[@R43]--[@R48]\], 6 non-Hodgkin lymphoma \[[@R49]--[@R54]\], 6 prostate cancer \[[@R55]--[@R60]\], 8 gastric cancer \[[@R61]--[@R67]\], 12 bladder cancer \[[@R68]--[@R79]\], 14 lung cancer \[[@R70], [@R80]--[@R92]\], and 15 breast cancer \[[@R23], [@R32], [@R93]--[@R105]\]. The detailed study selection process is shown in Figure [1](#F1){ref-type="fig"}. Table [1](#T1){ref-type="table"} presents the major characteristics of the 86 articles.

![Flow chart showing the selection process for the included studies](oncotarget-08-48488-g001){#F1}

###### Characteristics of the case--control studies included in the meta-analyses

  First author        Year   Ethnicity          Country^a^        Source of controls   Cancer site             Genotyping method     cases   controls                       
  ------------------- ------ ------------------ ----------------- -------------------- ----------------------- --------------------- ------- ---------- ----- ------ ------ -----
  Liu G               2007   Caucasian          USA               HB                   esophageal cancer       PCR-RFLP              75      92         16    144    160    32
  An                  2007   Caucasian          USA               HB                   head and neck cancera   PCR-RFLP              330     395        104   370    386    98
  Harth               2008   Caucasian          Germany           HB                   head and neck cancera   Real-time PCR         113     158        40    101    145    52
  Abbasi              2009   Caucasian          Germany           PB                   head and neck cancera   Real-time PCR         93      119        34    258    304    82
  Ji                  2010   Asian              Korea             HB                   head and neck cancera   PCR                   235     29         0     309    30     3
  Gugatschka          2011   Caucasian          Austria           PB                   head and neck cancera   TaqMan                116     133        42    171    208    83
  Smedby              2006   Caucasian          Sweden            PB                   non- Hodgkin lymphoma   PCR                   167     211        50    262    255    85
  Shen                2006   Caucasian          USA               PB                   non- Hodgkin lymphoma   Real-time PCR         199     189        57    226    238    70
  Song                2008   Asian              China             HB                   non- Hodgkin lymphoma   PCR-RFLP              256     47         4     265    35     3
  Baris               2009   Caucasian          Turkey            HB                   non- Hodgkin lymphoma   PCR-RFLP              13      16         4     15     27     10
  Worrillow           2009   Caucasian          England           PB                   non- Hodgkin lymphoma   TaqMan                270     265        79    316    335    79
  EI-Din              2013   Caucasian          Egypt             HB                   non- Hodgkin lymphoma   PCR-RFLP              30      37         14    38     44     18
  Capella G           2008   Mixed              Spain             PB                   gastric cancer          PCR-RFLP              110     96         38    444    532    159
  Zhou RM             2007   Asians             China             PB                   gastric cancer          PCR-RFLP              221     32         0     528    82     2
  Lou Y               2006   Asians             China             HB                   gastric cancer          PCR-RFLP              189     39         10    176    21     3
  Agalliu             2010   Caucasian          USA               PB                   prostate cancer         PCR-RFLP              545     575        120   527    528    166
  Agalliu             2010   African            USA               PB                   prostate cancer         PCR-RFLP              106     31         7     65     15     2
  Moreno V            2006   Caucasian          Spain             HB                   colorectal cancer       PCR                   95      91         100   77     72     63
  Hansen RD           2007   Caucasian          Denmark           PB                   colorectal cancer       TaqMan                159     191        46    333    354    108
  De Ruyck            2007   Caucasian          Belgium           HB                   Lung Cancer             PCR-RFLP              44      53         13    49     46     14
  Zienolddiny         2006   Caucasian          Norway            PB                   Lung Cancer             PCR                   119     102        54    120    121    49
  Matullo             2006   Caucasian          Europe            PB                   Lung Cancer             PCR-RFLP              49      48         19    418    506    170
  Hu                  2006   Asian              China             HB                   Lung Cancer             TaqMan                850     116        4     874    111    1
  Shen                2005   Asian              China             PB                   Lung Cancer             PCR                   109     9          0     99     14     0
  Huang               2006   Mixed              USA               NA                   Lung Cancer             PCR                   301     300        82    301    304    93
  Broberg             2005   Caucasian          Sweden            PB                   bladder cancer          PCR                   16      29         12    61     71     13
  Matullo             2005   Caucasian          Italy             HB                   bladder cancer          PCR-RFLP and TaqMan   92      153        47    103    155    47
  Matullo             2006   Caucasian          European          PB                   bladder cancer          TaqMan                48      60         16    418    506    170
  Schabath            2005   Mixed              USA               HB                   bladder cancer          PCR-RFLP              225     215        57    248    179    50
  Andrew              2006   Mixed              USA               PB                   bladder cancer          PCR-RFLP              113     145        38    205    251    51
  Garcia-Closas       2006   Caucasian          Spain             HB                   bladder cancer          PCR                   517     474        138   538    467    117
  Wu                  2006   Caucasian          USA               HB                   bladder cancer          PCR-RFLP              264     283        78    283    243    65
  Fontana             2008   Caucasian          French            HB                   bladder cancer          TaqMan                25      19         7     21     18     6
  Chang               2009   Asian              China             HB                   bladder cancer          PCR-RFLP              153     98         57    199    67     42
  Gangwar             2009   Asian              India             HB                   bladder cancer          PCR-RFLP              72      100        34    128    104    18
  Mittal              2012   Asian              India             PB                   bladder cancer          PCR                   78      100        34    128    104    18
  Ye                  2006   Caucasian          Sweden            PB                   esophageal cancer       PCR-RFLP              61      92         24    176    237    57
  Tse                 2008   Mixed              USA               HB                   esophageal cancer       TaqMan                117     150        43    199    206    49
  Pan                 2009   Caucasian          USA               HB                   esophageal cancer       TaqMan                16      20         1     201    185    48
  Pan                 2009   Caucasian          USA               HB                   esophageal cancer       TaqMan                137     163        43    201    185    48
  Huang               2012   Asian              China             HB                   esophageal cancer       PCR-RFLP              171     42         0     298    60     0
  Li                  2013   Asian              China             HB                   esophageal cancer       PCR-RFLP              342     56         2     351    47     2
  Han                 2005   Mixed              USA               PB                   Skin Cancer             TaqMan                88      99         19    342    373    121
  Wang LL             2009   Asian              China             HB                   colorectal cancer       PCR-RFLP              132     29         9     176    21     3
  Mahimkar MB         2010   Asian              India             NA                   oral cancer             PCR-RFLP              23      13         4     23     21     1
  Wang Y              2007   Caucasian          USA               HB                   oral cancer             PCR and Taqman        50      59         16    140    109    29
  Majumder M          2007   Asian              India             HB                   oral cancer             PCR                   269     208        52    205    146    36
  Crew                2007   NA                 USA               PB                   breast cancer           Taqman                415     478        138   490    454    139
  Jorgensen           2007   Caucasian          USA               PB                   breast cancer           Taqman                110     128        22    102    142    29
  Kuschel             2005   Australian         UK                PB                   breast cancer           TaqMan                1529    1530       497   1401   1437   430
  Lee                 2005   Asian              Korea             HB                   breast cancer           PCR                   475     50         3     401    41     3
  Bernard-Gallon      2008   NA                 France            HB                   breast cancer           Taqman                403     383        118   458    418    118
  Debniak             2006   Polish             Poland            PB                   breast cancer           PCR-RFLP              672     785        269   180    252    79
  Jakubowska          2010   Polish             Poland            HB                   breast cancer           PCR                   118     152        44    106    135    49
  Mechanic            2006   Caucasian          USA               PB                   breast cancer           PCR-RFLP              543     589        130   489    516    128
  Mechanic            2006   African-American   USA               PB                   breast cancer           PCR-RFLP              564     181        15    517    145    13
  Shen                2006   American           USA               PB                   breast cancer           Taqman                60      80         16    59     64     30
  Smith               2008   Caucasian          USA               HB                   breast cancer           PCR                   126     137        41    161    188    42
  Smith               2008   African-American   USA               HB                   breast cancer           PCR                   33      14         2     57     16     1
  Zhang               2005   Asian              China             PB                   breast cancer           PCR-RFLP              89      111        20    119    140    51
  Hussien             2012   Caucasian          Egypt             HB                   breast cancer           PCR                   12      45         43    25     50     25
  Jelonek             2010   Mixed              Poland            PB                   breast cancer           PCR-RFLP              41      59         21    85     123    23
  Wang                2010   Asian              China             PB                   breast cancer           PCR-RFLP              624     388        220   925    315    193
  Zhou                2012   Asian              Asia              PB                   Lung Cancer             PCR-RFLP              85      18         0     85     17     1
  Sakoda              2012   Caucasian          USA               PB                   Lung Cancer             TaqMan                326     329        89    610    685    182
  Qian                2011   Asian              China             PB                   Lung Cancer             PCR                   464     82         4     497    79     3
  Yin                 2009   Asian              China             HB                   Lung Cancer             PCR-RFLP              246     38         1     255    30     0
  Raaschou-Nielsen    2008   Caucasian          Denmark           PB                   Lung Cancer             PCR                   177     188        59    329    351    107
  Chang               2008   Latino-American    USA               PB                   Lung Cancer             WGA                   60      40         8     192    93     12
  Chang               2008   African-American   USA               PB                   Lung Cancer             WGA                   186     58         3     212    60     5
  Yin                 2007   Asian              China             HB                   Lung Cancer             PCR-RFLP              200     1          0     170    0      1
  Lopez-Cima          2007   Caucasian          Spain             HB                   Lung Cancer             PCR-RFLP              240     221        55    260    230    43
  Han                 2005   Mixed              USA               PB                   Skin Cancer             TaqMan                104     149        32    342    373    121
  Han                 2005   Mixed              USA               PB                   Skin Cancer             TaqMan                128     115        37    342    373    121
  Lovatt              2005   Caucasian          UK                PB                   Skin Cancer             PCR-RFLP              224     219        66    151    163    65
  Li                  2006   Mixed              USA               HB                   Skin Cancer             PCR                   242     290        70    273    259    71
  Millikan            2006   Caucasian          USA               PB                   Skin Cancer             PCR                   1039    1098       162   1039   1098   260
  Debniak             2006   Polish             Poland            mixed                Skin Cancer             PCR                   168     188        69    492    597    173
  Bau                 2007   Asian              Taiwan            HB                   prostate cancer         PCR                   62      39         22    310    106    63
  Mandal              2010   Asian              India             PB                   prostate cancer         PCR                   76      56         39    99     81     20
  Lavende             2010   African            America           HB                   prostate cancer         PCR and Taqman        146     39         5     510    116    5
  Dhillon             2011   Caucasian          Australia         NA                   prostate cancer         PCR-RFLP              71      37         8     80     42     10
  Yuan T              2011   Asian              China             HB                   gastric Cancer          PCR                   156     18         16    133    35     12
  Chen Z              2011   Asian              China             HB                   gastric Cancer          PCR-RFLP              75      118        15    220    111    8
  Zhang CZ            2009   Asian              China             HB                   gastric Cancer          PCR-RFLP              75      117        15    132    72     8
  Ruzzo A             2007   Caucasian          Italy             HB                   gastric Cancer          PCR-RFLP              23      26         20    41     67     13
  Deng Sl             2010   Asian              China             HB                   gastric Cancer          PCR                   132     15         13    118    31     11
  Wu JS               2014   Asian              China             HB                   HCC                     PCR                   138     58         22    181    70     26
  Sambuddha           2015   Asian              Northeast India   NA                   head and neck cancer    PCR                   32      40         8     57     31     4
  Benjamin            2015   Mexican            Mexica            HB                   osteosarcoma            PCR                   21      3          4     68     8      21
  Benjamin            2015   Mexican            Mexica            HB                   colorectal cancer       PCR                   74      26         8     81     23     15
  Benjamin            2015   Mexican            Mexica            HB                   breast cancer           PCR                   54      9          8     54     1      19
  Min Ni              2014   Asian              China             HB                   colorectal cancer       Real-time PCR         182     26         5     210    27     3
  Volha P. Ramaniuk   2014   Belarusians        Belarus           HB                   bladder cancer          PCR-RFLP              99      178        56    128    169    71
  Aneta Mirecka       2014   Polish             Poland            PB                   prostate cancer         real-time PCR         199     249        124   377    218    32

^a^ Country of first author.

Meta-analysis {#s2_2}
-------------

### Overall analysis {#s2_2_1}

In the dominant model, increased cancer risk was found with an odds ratio (OR) of 1.110 (95% confidence interval \[CI\] 1.078-1.143, P\<0.01). In the recessive model, significantly increased risk was determined with an OR of 1.059 (95% CI 1.013-1.108, P\<0.01). Furthermore, when the homozygote and heterozygote comparisons were performed, increased risk was identified, with an OR of 1.103 (95% CI 1.052-1.157, P\<0.01), and an OR of 1.106 (95% CI 1.072-1.141, P\<0.01), respectively. Overall, the results of our meta-analysis showed a significant association between the *ERCC2* polymorphism and cancer risk (Table [2](#T2){ref-type="table"}).

###### Results of overall and stratified meta-analyses

  Model (Comparison)                                Subgroup   No. of trials   I^2^(%)   *P*^a^               Fixed                Random               *P* for bias
  ------------------------------------------------- ---------- --------------- --------- -------------------- -------------------- -------------------- --------------
  homozygote comparison (Asn/Asn vs. Asp/Asp)       Total      95              68.3      0                    1.103(1.052,1.157)   1.170(1.060,1.293)   0.079
  PB                                                41         79.8            0         1.037(0.977,1.101)   1.074(0.922,1.250)   0.53                 
  HB                                                49         39              0.004     1.249(1.149,1.358)   1.283(1.135,1.450)   0.462                
  Asia                                              30         48.3            0.003     1.664(1.461,1.894)   1.734(1.371,2.192)   0.961                
  Caucasian                                         37         50.8            0         0.964(0.899,1.034)   1.019(0.913,1.137)   0.041                
  PCR                                               29         65              0         1.041(0.951,1.140)   1.175(0.983,1.404)   0.054                
  PCR-RFLP                                          38         62.5            0         1.160(1.068,1.260)   1.238(1.053,1.455)   0.054                
  Taqman                                            18         24.8            0.163     1.003(0.921,1.093)   0.983(0.878,1.100)   0.16                 
  Bladder cancer                                    12         56.4            0.008     1.370(1.198,1.566)   1.446(1.160,1.803)   0.191                
  Breast cancer                                     18         66.6            0         1.098(1.009,1.194)   1.042(0.871,1.246)   0.543                
  Esophageal cancer                                 7          0               0.62      1.219(0.945,1.571)   1.243(0.962,1.608)   0.074                
  Gastric cancer                                    8          65.3            0.005     1.517(1.167,1.972)   1.876(1.105,3.186)   0.258                
  Head and neck cancer                              6          52.4            0.062     0.993(0.814,1.212)   0.989(0.707,1.384)   0.909                
  Lung Cancer                                       16         0               0.533     1.043(0.901,1.207)   1.042(0.899,1.207)   0.386                
  Prostate cancer                                   7          93.5            0         1.570(1.314,1.874)   2.038(0.848,4.894)   0.419                
  Skin Cancer                                       7          59.9            0.021     0.784(0.689,0.893)   0.818(0.657,1.020)   0.448                
  Non- Hodgkin lymphoma                             6          0               0.782     0.998(0.811,1.229)   1.000(0.812,1.231)   0.505                
  heterozygote comparison (Asp/Asn vs. Asp/Asp)     Total      95              61.1      0                    1.106(1.072,1.141)   1.133(1.072,1.198)   0.111
  PB                                                41         64.7            0         1.061(1.020,1.104)   1.064(0.988,1.146)   0.889                
  HB                                                49         53.9            0         1.205(1.143,1.270)   1.229(1.128,1.339)   0.329                
  Asia                                              30         71.8            0         1.373(1.275,1.480)   1.287(1.105,1.499)   0.096                
  Caucasian                                         37         0               0.801     1.034(0.988,1.083)   1.034(0.987,1.082)   0.526                
  PCR                                               29         44.2            0.006     1.057(0.996,1.121)   1.076(0.982,1.180)   0.281                
  PCR-RFLP                                          38         70              0         1.187(1.126,1.251)   1.203(1.081,1.338)   0.745                
  Taqman                                            18         14.5            0.28      1.030(0.974,1.090)   1.039(0.973,1.109)   0.348                
  Bladder cancer                                    12         31.2            0.142     1.235(1.128,1.353)   1.265(1.125,1.423)   0.231                
  Breast cancer                                     18         70.7            0         1.086(1.025,1.149)   1.101(0.972,1.248)   0.42                 
  Esophageal cancer                                 7          0               0.994     1.213(1.051,1.401)   1.213(1.051,1.401)   0.932                
  Gastric cancer                                    8          91.1            0         1.209(1.038,1.409)   1.066(0.614,1.848)   0.491                
  Head and neck cancer                              6          27.4            0.229     1.114(0.977,1.271)   1.121(0.950,1.323)   0.334                
  Lung Cancer                                       16         0               0.808     1.000(0.918,1.090)   1.001(0.918,1.091)   0.294                
  Prostate cancer                                   7          78.4            0         1.281(1.140,1.440)   1.297(0.965,1.743)   0.879                
  Skin Cancer                                       7          36.5            0.15      1.018(0.938,1.105)   1.023(0.913,1.146)   0.868                
  Non- Hodgkin lymphoma                             6          27.7            0.227     1.038(0.907,1.187)   1.047(0.881,1.244)   0.938                
  dominant model((Asn/Asn+Asp/Asn) vs. Asp/Asp)     Total      95              69.3      0                    1.110(1.078,1.143)   1.143(1.078,1.212)   0.126
  PB                                                41         75.9            0         1.060(1.021,1.101)   1.067(0.981,1.160)   0.754                
  HB                                                49         56.6            0         1.217(1.158,1.278)   1.237(1.139,1.343)   0.587                
  Asia                                              30         73.4            0         1.416(1.321,1.518)   1.336(1.153,1.547)   0.13                 
  Caucasian                                         37         3.2             0.414     1.020(0.976,1.065)   1.021(0.976,1.068)   0.102                
  PCR                                               29         47.4            0.003     1.053(0.996,1.113)   1.091(0.999,1.191)   0.137                
  PCR-RFLP                                          38         74.5            0         1.191(1.133,1.251)   1.216(1.091,1.356)   0.647                
  Taqman                                            18         11.5            0.317     1.026(0.972,1.082)   1.028(0.968,1.093)   0.908                
  Bladder cancer                                    12         50.2            0.024     1.266(1.162,1.379)   1.309(1.148,1.494)   0.242                
  Breast cancer                                     17         73.4            0         1.091(1.034,1.151)   1.083(0.958,1.223)   0.962                
  Esophageal cancer                                 7          0               0.989     1.214(1.057,1.394)   1.214(1.057,1.394)   0.236                
  Gastric cancer                                    8          90.7            0         1.277(1.106,1.474)   1.229(0.745,2.027)   0.88                 
  Head and neck cancer                              6          50.7            0.071     1.091(0.963,1.236)   1.104(0.908,1.343)   0.493                
  Lung Cancer                                       15         0               0.763     1.010(0.931,1.097)   1.010(0.931,1.097)   0.474                
  Prostate cancer                                   7          89.8            0         1.353(1.213,1.509)   1.407(0.951,2.081)   0.71                 
  Skin Cancer                                       7          37.6            0.142     0.968(0.895,1.046)   0.978(0.877,1.090)   0.682                
  Non- Hodgkin lymphoma                             6          9.4             0.356     1.033(0.909,1.173)   1.035(0.901,1.189)   0.932                
  recessive model (Asn/Asn vs. (Asp/Asp+Asp/Asn))   Total      95              62.7      0                    1.059(1.013,1.108)   1.108(1.016,1.208)   0.098
  PB                                                41         76.4            0         1.010(0.954,1.069)   1.044(0.914,1.192)   0.501                
  HB                                                49         30.6            0.025     1.157(1.070,1.252)   1.178(1.059,1.310)   0.481                
  Asia                                              30         35.8            0.032     1.445(1.275,1.637)   1.515(1.240,1.852)   0.668                
  Caucasian                                         37         52.2            0         0.954(0.894,1.019)   1.006(0.906,1.115)   0.055                
  PCR                                               29         64.2            0         1.022(0.939,1.113)   1.131(0.959,1.335)   0.107                
  PCR-RFLP                                          38         53              0         1.087(1.006,1.175)   1.147(1.002,1.314)   0.152                
  Taqman                                            18         28.8            0.123     0.987(0.911,1.609)   0.958(0.859,1.069)   0.082                
  Bladder cancer                                    12         48.6            0.029     1.225(1.080,1.389)   1.271(1.052,1.536)   0.189                
  Breast cancer                                     17         60.1            0.001     1.062(0.981,1.149)   1.018(0.874,1.186)   0.421                
  Esophageal cancer                                 7          0               0.615     1.102(0.869,1.398)   1.130(0.888,1.437)   0.086                
  Gastric cancer                                    8          39              0.119     1.563(1.215,2.011)   1.739(1.190,2.541)   0.341                
  Head and neck cancer                              6          35.4            0.171     0.951(0.790,1.144)   0.944(0.729,1.223)   0.815                
  Lung Cancer                                       15         0               0.806     1.046(0.910,1.203)   1.046(0.910,1.203)   0.495                
  Prostate cancer                                   7          92.4            0         1.406(1.186,1.667)   1.851(0.846,4.050)   0.357                
  Skin Cancer                                       7          63.4            0.012     0.781(0.691,0.883)   0.810(0.653,1.006)   0.557                
  Non- Hodgkin lymphoma                             6          0               0.619     0.987(0.813,1.200)   0.989(0.814,1.203)   0.646                

^a^ *P* for heterogeneity.

### Subgroup analysis {#s2_2_2}

In order to evaluate the effects of specific study characteristics on the association between the *ERCC2* polymorphism and cancer risk, we performed subgroup analysis if there were 6 or more studies. The ORs and 95% CIs were obtained from the subgroups of control source, ethnicity, genotyping method, and type of cancer. For control source subgroup, we found a significant association between the *ERCC2* polymorphism and cancer risk when the source of the controls was hospital-based (HB). Meanwhile, when the studies recruited population-based (PB) control, no association was found. For ethnicity, no significant association was detected in Caucasians, but significant associations were observed in Asians. When stratified according to the genotyping method, significant associations were observed when the method was polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). By comparison, no relationship was found when the methods used were PCR and TaqMan assay. According to the type of cancer, the *ERCC2* polymorphism was associated with a significantly higher risk of bladder cancer. In contrast, we observed no association between this polymorphism and breast cancer. Similarly, the results of subgroups of other cancers indicated no association with the *ERCC2* polymorphism, including head and neck, lung, prostate, and skin cancers and non-Hodgkin lymphoma. For the esophageal cancer group, a significant association was obtained in the heterozygote comparison, but not in the homozygote comparison and the recessive model. In the group with gastric cancer, the *ERCC2* polymorphism was confirmed to increase the risk of cancer in the homozygote comparison and the recessive model, but not in the heterozygote comparison and the dominant model. The detailed results are shown in Table [2](#T2){ref-type="table"}.

### Test of heterogeneity {#s2_2_3}

High heterogeneity was observed after the data were pooled (homozygote comparison: *P* for heterogeneity = 0, I^2^ = 68.3%). As shown in Table [2](#T2){ref-type="table"}, when the subjects were stratified on the basis of the control source, high heterogeneity remained with PB controls (homozygote comparison: *P* for heterogeneity = 0, I^2^ = 79.8%). Additionally, in analyses of ethnicity, moderate heterogeneity was found in Asian studies (homozygote comparison: *P* for heterogeneity = 0.003, I^2^ = 48.3%), and high heterogeneity was found in Caucasian studies (homozygote comparison: *P* for heterogeneity = 0, I^2^ = 50.8%). Moreover, in analyses of genotyping methods, low heterogeneity was detected in the TaqMan group (homozygote comparison: *P* for heterogeneity = 0.163, I^2^ = 24.8%), but high heterogeneity was found in the PCR (homozygote comparison: *P* for heterogeneity = 0, I^2^ = 65%) and PCR-RFLP groups (homozygote comparison: *P* for heterogeneity = 0, I^2^ = 62.5%). Furthermore, heterogeneity was not detected in esophageal cancer studies (homozygote comparison: *P* for heterogeneity = 0.62, I^2^ = 0.0%), lung cancer studies (homozygote comparison: *P* for heterogeneity = 0.533, I^2^ = 0.0%), and non-Hodgkin lymphoma studies (homozygote comparison: *P* for heterogeneity = 0.782, I^2^ = 0.0%). Nonetheless, high heterogeneity was still present in studies of prostate cancer (homozygote comparison: *P* for heterogeneity = 0, I^2^ = 93.5%), bladder cancer (homozygote comparison: *P* for heterogeneity = 0.008, I^2^ = 56.4%), breast cancer (homozygote comparison: *P* for heterogeneity = 0, I^2^ = 66.6%), gastric cancer (homozygote comparison: *P* for heterogeneity = 0.005, I^2^ = 65.3%), head and neck cancer (homozygote comparison: *P* for heterogeneity = 0.062, I^2^ = 52.4%), and skin cancer (homozygote comparison: *P* for heterogeneity = 0.021, I^2^ = 59.9%).

### Publication bias and sensitivity analysis {#s2_2_4}

We used the Begg\'s funnel plot to estimate publication bias. There was no statistical evidence of publication bias in the overall analysis under each model (Figure [2](#F2){ref-type="fig"}). Table [2](#T2){ref-type="table"} shows the P details for bias. We also removed studies one by one to determine their effect on the test of heterogeneity, and evaluated the stability of the overall results; the results did not change in the overall analysis ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) neither in other analysis.

![**(A)** Begg\'s funnel plot for the publication bias test in the overall analysis under homozygote comparison. **(B)** Begg\'s funnel plot for the publication bias test in the overall analysis under heterozygote comparison. **(C)** Begg\'s funnel plot for the publication bias test in the overall analysis under dominant model. **(D)** Begg\'s funnel plot for the publication bias test in the overall analysis under recessive model.](oncotarget-08-48488-g002){#F2}

Trial sequential analysis (TSA) {#s2_3}
-------------------------------

In the overall analysis for homozygote comparison, the required information size was 72,622 patients to demonstrate the issue (Figure [3](#F3){ref-type="fig"}), and the result showed that the Z-curve had crossed the trial monitoring boundary before reaching the required information size, indicating that the cumulative evidence is adequate and further trials are unnecessary.

![TSA for overall analysis under homozygote comparison](oncotarget-08-48488-g003){#F3}

DISCUSSION {#s3}
==========

Nowadays, cancer is one of the most important global public health problems \[[@R106]\]. Personalized analysis and improved methods of cancer diagnoses can be provided, based on an understanding of the association between genetic polymorphisms and cancer risk \[[@R107]\]. In the relationship between gene polymorphisms and cancer risk, the *ERCC2* Asp312Asn polymorphism is an important risk factor. Impaired DNA repair capacity is a risk factor for the development of cancer. The *ERCC2* Asp312Asn polymorphism influences DNA repair through the NER pathway. To date, many publications have shown an association between the *ERCC2* Asp312Asn polymorphism and risk of cancer. However, the results remain controversial. In order to resolve this conflict, we performed a meta-analysis that evaluates the relationship between the *ERCC2* Asp312Asn polymorphism and risk of cancer.

In our meta-analysis, the association of the *ERCC2* Asp312Asn polymorphism with the risk of cancer was evaluated in 38,848 cases and 48,928 controls. A significant association was observed between the *ERCC2* Asp312Asn polymorphism and overall cancer risk in all genetic models. To the best of our knowledge, this is the most comprehensive meta-analysis on this topic until now. Moreover, the result of the TSA indicated that the cumulative evidence is adequate and further trials are unnecessary in the overall analysis for homozygote comparison.

In the subgroup analysis based on ethnicity, a significantly increased cancer risk was observed in Asian populations, but not in Caucasian populations. One possible reason for these discrepancies is that different ethnicities may have distinct genetic backgrounds, and therefore, tumor susceptibility can be influenced by ethnicity \[[@R108]\]. Moreover, this may indicate that these groups have distinct environmental or genetic cancer co-etiologies \[[@R109]\]. In subgroup analysis based on the control source, we found that a significantly increased cancer risk was observed in HB studies, but not in PB studies. The former may have certain biases for such controls and may only represent a sample of an ill-defined reference population. Furthermore, HB controls may not be representative of the general population or it may be that numerous subjects in the PB controls were individuals susceptible to cancer \[[@R110]\]. In the subgroup analysis based on the genotyping method, a significantly increased cancer risk was found in the PCR-RFLP studies, but not in the PCR or TaqMan studies. A possible reason for this may be that the different genotyping methods are specialized for different aspects, and the results would be more accurate and reliable if the same genotyping method was applied in different studies \[[@R111]\].

In the subgroup analysis according to the cancer site, a significant association with the *ERCC2* Asp312Asn polymorphism was observed for bladder, esophageal, and gastric cancers; however, no significant association was observed for breast, head and neck, lung, prostate, and skin cancers, and non- Hodgkin lymphoma. Some previous meta-analyses assessed the effect of the *ERCC2* Asp312Asn polymorphism on the risk of these cancers and reached conclusions consistent with those of our study. For example, Li et al. \[[@R19]\] and Wen et al. \[[@R14]\] suggested that the *ERCC2* Asp312Asn polymorphism might be associated with an increased risk of bladder cancer and esophageal cancer, respectively. Yin et al. \[[@R48]\] showed that this polymorphism might be a potential biomarker of gastric cancer susceptibility in the overall population. In contrast, Yan et al. \[[@R21]\], Hu et al. \[[@R11]\], and Zhu et al. \[[@R112]\] suggested that the *ERCC2* Asp312Asn polymorphism was not associated with breast cancer, head and neck cancer, and skin cancer, respectively. Moreover, Chen et al. \[[@R113]\], Feng et al. \[[@R12]\], and Ma et al. \[[@R114]\] suggested that the *ERCC2* Asp312Asn polymorphism contributed to the risk of non-Hodgkin lymphoma, lung cancer, and prostate cancer, respectively. Because we only included studies published from 2005 to 2016, we drew different conclusions in lung cancer and prostate cancer studies. Therefore, more research should be undertaken in the future. Moreover, the exact mechanism for the associations between different cancer sites and the *ERCC2* Asp312Asn polymorphism is not clear; the mechanism of carcinogenesis may differ between different cancer sites and the *ERCC2* genetic variants may exert varying effects in different cancers \[[@R115]\].

Notably, HCC, osteosarcoma, oral cancer, and colorectal cancer were not included for further analysis as there were fewer than 6 studies available for analysis for such cancers. Wu et al. indicated that the *ERCC2* Asp312Asn polymorphism was not associated with the development of HCC \[[@R24]\]. Gomez-Diaz et al. demonstrated no relationship between *ERCC2* Asp312Asn polymorphism and osteosarcoma \[[@R23]\]. Interestingly, based on a study by Mahimkar et al. this polymorphism was associated with an overall increase in chromosomal damage in oral cancer \[[@R25]\]. Wang et al. \[[@R35]\] observed a slightly lower statistical significance between the *ERCC2* Asp312Asn polymorphism and colorectal cancer. In fact, this polymorphism has also been shown to be related to other diseases; previous studies have indicated that it may have a role in the development of ultraviolet-related diseases, such as maturity onset cataract. \[[@R116]\]. However, no significant association of this polymorphism was found with either idiopathic azoospermia \[[@R117]\] or arsenic-related skin lesions \[[@R118]\]. Therefore, the equivocal association between the *ERCC2* Asp312Asn polymorphism and some diseases remains to be confirmed.

Heterogeneity is a major concern for meta-analysis \[[@R119]\]. In our overall analysis, high heterogeneity was observed for all genetic models. However, when data were pooled in to subgroups according the control source, ethnicity, genotyping method, and cancer type, the heterogeneity decreased. Sensitivity analysis showed that the results have sufficient statistical power. There are some limitations of our meta-analysis that should be addressed. First, subgroup analysis cannot be conducted based on sex, age, lifestyle, and other factors owing to insufficient data. Second, some cancers, such as oral cancer and colorectal cancer, were not suitable for further analysis because of the small sample sizes. Thus, more studies on these cancers should be conducted in the future. Third, a single gene has only a moderate effect on cancer development; hence, the *ERCC2* gene may influence susceptibility of cancer along with other genes. However, enough data for further analysis is not available. Finally, only published articles were included in the analysis; therefore, unpublished data may modify our conclusions.

In summary, our meta-analysis suggested that the *ERCC2* Asp312Asn polymorphism is associated with increased cancer risk. A significantly increased cancer risk was observed in Asian populations, but not in Caucasian populations. Moreover, our results indicated that this polymorphism is associated with bladder, esophageal, and gastric cancers, but not with breast, head and neck, lung, prostate, and skin cancers, and non-Hodgkin lymphoma. In addition, stratification analyses based on the control source also indicated that this polymorphism was associated with cancer risk in the HB populations, but not in the PB populations. In subgroup analysis according to the genotyping method, a significantly increased cancer risk was found in the PCR-RFLP studies, but not in the PCR and TaqMan studies. Considering the limitations of this study, further multi-center, well-designed research should be undertaken in the future.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

A systematic search of articles relating to the *ERCC2* Asp312Asn polymorphism and cancer was conducted by 2 researchers, using the PubMed, EMBASE, Science Direct, Web of Science and the China National Knowledge Infrastructure (CNKI) databases. The search included studies published between January 1, 2005 and January 1, 2016. The search strategy was based on various combinations of the following terms: "xeroderma pigmentosum group d protein "\[MeSH Terms\] OR "xeroderma pigmentosum group d protein" \[All Fields\] OR "ercc2" \[All Fields\]) AND Asp312Asn \[All Fields\] AND ("neoplasms" \[MeSH Terms\] OR "neoplasms" \[All Fields\] OR "cancer" \[All Fields\]. In addition, the reference lists of the publications identified were searched for further relevant studies. The PRISMA Checklist was used for this meta-analysis ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}).

Selection criteria {#s4_2}
------------------

The following inclusion criteria were set and reviewed by two independent investigators: (I) case-control study; (II) evaluation of the *ERCC2* Asp312Asn polymorphism and cancer; and (III) detailed data available for calculating ORs and the corresponding 95% CIs. Studies were excluded if they: (I) had no control population; (II) were review articles or previous meta-analyses; (III) contained insufficient or duplicate data; or (IV) had no full text available.

Data extraction {#s4_3}
---------------

Two authors performed data extraction independently. For all publications, the following data were extracted: first author, year of publication, ethnicity of the population, country, source of cases and controls, cancer site, genotyping method, and number of cases and controls.

Trial sequential analysis {#s4_4}
-------------------------

To evaluate whether our meta-analysis had sufficient sample size to reach firm conclusions about the effect of interventions \[[@R120]\], TSA was used in this meta-analysis. If the cumulative Z curve in results exceeds the TSA boundary, a sufficient level of evidence for the anticipated intervention effect may have been reached and no further trials are needed. However, when the Z curve does not exceed the TSA boundaries and the required information size has not been reached, evidence to draw a conclusion is insufficient \[[@R121]\]. We used two-sided tests, type I error set at 5%, and power set at 80%. The required information size was calculated based on a relative risk reduction of 10%. Trials ignored in interim appear to be due to too low use of information (\<1.0%) by the software. TSA was performed using the TSA software (version 0.9.5.5).

Statistical analysis {#s4_5}
--------------------

The primary objective of our meta-analysis was to calculate ORs and their 95% CIs to evaluate the association between *ERCC2* Asp312Asn and cancer risks. In our included studies, no clear models had been chosen; thus, the following genetic models were used: homozygote comparison (Asn/Asn vs. Asp/Asp), heterozygote comparison (Asp/Asn vs. Asp/Asp), recessive model (Asn/Asn vs. Asp/Asp+Asp/Asn), and dominant model (Asn/Asn+Asp/Asn vs. Asp/Asp). The statistical heterogeneity assumption was evaluated using I^2^ statistics to quantify any inconsistency arising from inter-research variability that was derived from heterogeneity instead of random chance \[[@R107]\]. An I^2^ value from 0-25% indicates low heterogeneity, 25-50% moderate heterogeneity and ≥50% high heterogeneity \[[@R122]\]. Two models (fixed-effect model and random-effect model) were used for analysis \[[@R123]\]. When I^2^\< 50%, we used a fixed effect model and when I^2^ ≥50%, we performed a random effect model \[[@R124], [@R125]\]. We used sensitivity analyses by omitting each study in turn to determine the effect of heterogeneity on the test, and evaluated the stability of the overall results \[[@R107]\]. Potential publication bias was assessed using the Begg\'s linear regression test \[[@R126]\]. Notably, subgroup analysis was not performed when there were fewer than 6 studies available, because the small number may have resulted in insufficient power \[[@R107]\]. All statistical analyses were performed using the STATA statistical software package (version 12.0; StataCorp, College Station, TX).
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NER

:   nucleotide excision repair

ERCC2

:   excision repair cross-complementing group 2

XPD

:   Xeroderma pigmentosum group D

TFIIH

:   transcription factor IIH

SNPs

:   single nucleotide polymorphisms

Asn

:   asparagine amino acid

HB

:   hospital-based

PB

:   population-based

HCC

:   hepatocellular cancer

CNKI

:   China National Knowledge Infrastructure

TSA

:   trial sequential analysis
